This episode currently has no reviews.
Submit ReviewGilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How much will it cost us? But Riley Griffin and Emma Court report that the Pharmaceutical industry is hoping Covid-19 will give it a chance to rebrand; and get the focus off drug prices.
See omnystudio.com/listener for privacy information.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review